Wall Street's M&A Chatter From January 6-8

The following are the M&A deals, rumors and chatter circulating on Wall Street for Friday January 6 through Sunday January 8, 2017.

Invitae Acquires AltaVoice for $5M in Stock at Closing Plus Up to $10M Based on Milestones

The Deal:

Invitae Corp NVTA announced it has acquired AltaVoice, a privately owned, patient-centered data company with a global platform for collecting, curating, coordinating, and delivering safeguarded data from patients and clinicians. Invitae purchased all of AltaVoice's stock in exchange for $5 million in Invitae common stock issuable upon closing and up to an additional $10 million in Invitae common stock issuable based on certain future milestones.

Invitae closed Friday at $8.54, down 1.61 percent.

Mast Therapeutics, Savara Sign Merger Agreement; Deal Values Mast at $36.5M

The Deal:

Mast Therapeutics Inc MSTX and Savara Inc. announced Saturday that the two companies have entered into a definitive merger agreement, valuing Mast at $36.5 million. Current Mast stockholders will collectively own approximately 24 percent, and Savara stockholders will collectively own approximately 76 percent, of the combined company on a pro-forma basis.

Mast Therapeutics closed at $0.10 on Friday, up 3.02 percent.

Merrimack Pharmaceuticals Confirms Plan to Sell ONIVYDE, Generic Version of DOXIL to Ipsen for Up to $1.025B

The Deal:

Merrimack Pharmaceuticals Inc MACK confirmed a Reuters report Sunday that it has entered into a definitive asset purchase and sale agreement with Ipsen IPSEY sell its first commercial product ONIVYDE and its generic version of DOXIL in a transaction valued at up to $1.025 billion, plus up to $33 million in net milestone payments. The transaction is expected to be completed in Q1 of 2017.

Merrimack closed at $3.60 on Friday, down 5.26 percent.